CAR-T Cell Therapies Going in Vivo

Why It Matters

In‑vivo CAR‑T could transform cell therapy from a niche, high‑cost treatment into a scalable, off‑the‑shelf biologic, reshaping market dynamics and patient access. The wave of multibillion‑dollar deals signals confidence that the technology will soon become a mainstream therapeutic class.

Key Takeaways

• Lilly to acquire Kelonia for $7 B, $3.25 B upfront.
• KLN‑1010 showed 100% MRD‑negative response in early trial.
• Big pharma deals total over $15 B in in‑vivo CAR‑T space.
• In‑vivo platforms promise off‑the‑shelf, scalable cell therapies.
• AI and LNP tech accelerate next‑gen in‑vivo CAR‑T development.

Pulse Analysis

The transition from ex‑vivo to in‑vivo CAR‑T reflects a fundamental engineering breakthrough: delivering gene‑editing payloads directly to a patient’s T cells. Traditional ex‑vivo products require individualized manufacturing, leukapheresis, and costly clean‑room processing, limiting scalability and driving prices toward $1 million per treatment. In‑vivo platforms, whether lentiviral vectors or lipid‑nanoparticle (LNP) mRNA carriers, bypass these steps, enabling an off‑the‑shelf drug that can be produced in bulk and administered via a simple injection. This shift promises not only lower production costs but also the ability to repeat‑dose or fine‑tune CAR expression, expanding therapeutic windows beyond the one‑shot paradigm.

The market response has been swift and sizable. Eli Lilly’s $7 billion Kelonia deal, AstraZeneca’s $1 billion EsoBiotec acquisition, Gilead’s $350 million purchase of Interius, and AbbVie’s $2.1 billion takeover of Capstan together represent more than $15 billion of capital flowing into the space within 12 months. These transactions secure diverse platforms—lentiviral ENaBL, circular RNA, and LNP‑based mRNA—each targeting hematologic malignancies and, increasingly, autoimmune diseases. Early clinical data, such as KLN‑1010’s 100% MRD‑negative response and Interius’s INT2104 first‑in‑human trial in Europe, provide tangible proof points that investors and pharma executives view as de‑risking milestones.

Technical advances are accelerating the pipeline. Engineered viral vectors now achieve precise T‑cell tropism, while next‑generation LNPs can bypass the liver and deliver payloads directly to immune cells. Artificial intelligence is being leveraged to optimize vector design and predict immunogenicity, shortening discovery cycles for startups like Sail Biomedicines and Mirai Bio. As these tools mature, in‑vivo CAR‑T could move from late‑stage trials to first‑line indications, democratizing cell therapy across a broader patient population and potentially reshaping the economics of oncology and immune‑modulating treatments.